GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fuan Pharmaceutical (Group) Co Ltd (SZSE:300194) » Definitions » Return-on-Tangible-Asset

Fuan Pharmaceutical (Group) Co (SZSE:300194) Return-on-Tangible-Asset : 5.29% (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Fuan Pharmaceutical (Group) Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Fuan Pharmaceutical (Group) Co's annualized Net Income for the quarter that ended in Mar. 2025 was ¥276 Mil. Fuan Pharmaceutical (Group) Co's average total tangible assets for the quarter that ended in Mar. 2025 was ¥5,225 Mil. Therefore, Fuan Pharmaceutical (Group) Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was 5.29%.

The historical rank and industry rank for Fuan Pharmaceutical (Group) Co's Return-on-Tangible-Asset or its related term are showing as below:

SZSE:300194' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -11.53   Med: 5.02   Max: 9.9
Current: 4.34

During the past 13 years, Fuan Pharmaceutical (Group) Co's highest Return-on-Tangible-Asset was 9.90%. The lowest was -11.53%. And the median was 5.02%.

SZSE:300194's Return-on-Tangible-Asset is ranked better than
58.77% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 2.68 vs SZSE:300194: 4.34

Fuan Pharmaceutical (Group) Co Return-on-Tangible-Asset Historical Data

The historical data trend for Fuan Pharmaceutical (Group) Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fuan Pharmaceutical (Group) Co Return-on-Tangible-Asset Chart

Fuan Pharmaceutical (Group) Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.45 -6.77 4.31 4.63 5.41

Fuan Pharmaceutical (Group) Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.43 7.22 6.53 -1.67 5.29

Competitive Comparison of Fuan Pharmaceutical (Group) Co's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Fuan Pharmaceutical (Group) Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fuan Pharmaceutical (Group) Co's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fuan Pharmaceutical (Group) Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Fuan Pharmaceutical (Group) Co's Return-on-Tangible-Asset falls into.


;
;

Fuan Pharmaceutical (Group) Co Return-on-Tangible-Asset Calculation

Fuan Pharmaceutical (Group) Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=279.837/( (5177.502+5172.598)/ 2 )
=279.837/5175.05
=5.41 %

Fuan Pharmaceutical (Group) Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=276.196/( (5172.598+5276.719)/ 2 )
=276.196/5224.6585
=5.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Fuan Pharmaceutical (Group) Co  (SZSE:300194) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Fuan Pharmaceutical (Group) Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Fuan Pharmaceutical (Group) Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Fuan Pharmaceutical (Group) Co Business Description

Traded in Other Exchanges
N/A
Address
No.1 Huanan 1 Road, Changshou District, Chongqing, CHN, 401254
Fuan Pharmaceutical (Group) Co Ltd is mainly engaged in the production and sales of bulk drugs and preparations. The company mainly deals with anti-infective, anti-tumor, mental nervous system, cardiovascular and cerebrovascular, digestive system, endocrine and metabolic, bone and muscle systems. Its products include penicillin and cephalosporins.
Executives
Wu Xiong Hui Executives
Huang Tao Directors, executives
Feng Jing Executives
Yu Xue Song Directors, executives
Hong Rong Chuan Executives
Tang Qin Secretary, Director
Wang Tian Xiang Director
Sun Yong Ping Executives
Jiang Chen Directors, executives
Huang Dao Fei Supervisors
Wen Min Director
Zhou Xu Dong Executives
Zhou Zhong Sheng Supervisors

Fuan Pharmaceutical (Group) Co Headlines

No Headlines